Adicet Bio (Nasdaq: ACET) details Q2 loss, cash runway and trial plans
Rhea-AI Filing Summary
Adicet Bio, Inc. reported second-quarter 2026 results and outlined upcoming milestones for its gamma delta T cell therapy pipeline. For the quarter ended June 30, 2026, research and development expenses were $18.5 million, general and administrative expenses were $3.9 million, and net loss was $21.4 million, or $1.99 per basic and diluted share. Cash, cash equivalents and short-term investments totaled $118.2 million as of June 30, 2026, which the company expects will fund operations into the second half of 2027.
The company plans a Phase 1 clinical update in the third quarter of 2026 for prulacabtagene leucel in lupus nephritis and systemic lupus erythematosus, including data from 22 patients with at least 6 months of follow-up, 13 with at least 12 months. Adicet is advancing a potential pivotal trial design in lupus nephritis anticipated to start in the second half of 2026, subject to regulatory clearance. A regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer is expected in the third quarter of 2026, with Phase 1 enrollment anticipated in the fourth quarter of 2026, and an update on its in vivo CAR-T platform is planned for the second half of 2026. The company appointed board member Lloyd Klickstein, M.D., Ph.D., as Interim Chief Medical Officer.
Positive
- None.
Negative
- None.
Filing Explained
At June 30, reported liquid resources were lower than year-end, while Adicet states they fund operations into the second half of 2027.
This Form 8-K furnishes, rather than files, Adicet’s second-quarter results; as of June 30, 2026, cash, cash equivalents and short-term investments were
For the six months ended June 30, 2026, operating expenses were
Working capital was
8-K Event Classification
Key Figures
Key Terms
allogeneic gamma delta T cell therapies medical
in vivo CAR-T medical
lupus nephritis medical
metastatic castration-resistant prostate cancer medical
prostate-specific membrane antigen medical
Earnings Snapshot
The company expects its cash, cash equivalents and short-term investments as of June 30, 2026, to fund operating expenses into the second half of 2027.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were Adicet Bio (ACET) key financial results for Q2 2026?
What clinical update is Adicet Bio (ACET) planning for prula-cel in LN and SLE?
What are Adicet Bio’s (ACET) plans for a pivotal trial in lupus nephritis?
What is the development timeline for ADI-212 in mCRPC at Adicet Bio (ACET)?
How long does Adicet Bio (ACET) expect its cash to fund operations?
Who is Adicet Bio’s (ACET) Interim Chief Medical Officer and what is his background?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: ( |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 5, 2026, Adicet Bio, Inc. announced its financial results for the quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
99.1 |
|
Press Release of Adicet Bio, Inc. dated August 5, 2026, furnished herewith. |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
ADICET BIO, INC. |
|
|
|
|
|
Date: August 5, 2026 |
|
By: |
/s/ Nick Harvey |
|
|
Name: |
Nick Harvey |
|
|
Title: |
Chief Financial Officer |
Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
Company to provide a comprehensive Phase 1 clinical update for prulacabtagene leucel (prula-cel, formerly ADI-001), featuring data from 22 patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) with a minimum of 6 months follow-up, including 13 patients with at least 12 months of follow-up; topline results now anticipated in 3Q/2026
Productive interactions with the U.S. Food and Drug Administration (FDA) informing potential pivotal trial design for LN, supporting planned start up activities in 2H/2026
On track for regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer (mCRPC) in 3Q/2026 with enrollment anticipated to begin 4Q/2026, pending regulatory clearance
Advancing in vivo CAR-T platform and pipeline
REDWOOD CITY, Calif. – August 5, 2026 – Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2026.
“At Adicet, we continue to advance prula-cel toward our next important clinical milestone, with a Phase 1 clinical update now expected in the third quarter of 2026. The additional follow-up time will allow us to deliver a more comprehensive and mature dataset, including 22 LN/SLE patients with a minimum of 6 months of follow-up, 13 of whom are expected to have reached at least 12 months of follow-up,” said Chen Schor, President and Chief Executive Officer of Adicet Bio. “We also had productive interactions with the FDA to align on overall clinical design for a potential pivotal trial for prula-cel in LN, further supporting a clear regulatory path forward. Furthermore, we anticipate sharing additional clinical updates for prula-cel in the second half of 2026 in patients with systemic sclerosis.”
Mr. Schor continued, “Beyond prula-cel, we are continuing to advance ADI-212 toward Phase 1 alongside our differentiated in vivo CAR-T platform and pipeline targeting hematologic malignancies and solid tumors. With several planned milestones ahead in 2026, including anticipated clinical data readouts in LN and SLE in the third quarter, clinical data in systemic sclerosis in the second half of the year, and an update on our in vivo CAR T platform and pipeline, we look forward to executing our strategic priorities and positioning the company for long-term value creation.”
Second Quarter 2026 and Recent Operational Highlights:
Autoimmune diseases
Solid tumor indications
In Vivo CAR-T Program and Pipeline
Corporate Update
Financial Results for Second Quarter 2026:
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
Forward-Looking Statements
This press release contains “forward-looking statements” of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: clinical development of Adicet’s product candidates, including future plans or expectations
for prula-cel in autoimmune diseases and the potential safety, tolerability and efficacy for the treatment of autoimmune diseases and cancer; expectations regarding future alignment with the FDA on regulatory path to approval and discussions to date; timing and success of the Phase 1 clinical trial of prula-cel in multiple autoimmune indications, including timing and expectations for enrollment and future data releases; expectations regarding the timing and initiation of a pivotal study for prula-cel in LN or LN and SLE patients; the preclinical and clinical development of ADI-212, including the timing of regulatory filings, clinical startup activities, clinical updates and future data releases; the timing of initiation of enrollment of a Phase 1 trial for ADI-212 in mCRPC; expectations regarding the potential potency of ADI-212; timing of updates to the Company’s in vivo CAR T platform pipeline; ongoing preclinical programs and activities relating to autoimmune diseases, hematological malignancies and solid tumors; and expectations regarding Adicet’s uses of capital, expenses and financial results, including the expected cash runway.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of global economic conditions and public health emergencies on Adicet’s business and financial results, including with respect to disruptions to our preclinical and clinical studies, business operations, employee hiring and retention, and ability to raise additional capital; Adicet’s ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including interim results, from a preclinical or clinical study may not necessarily be predictive of the results of future or ongoing studies; clinical studies may fail to demonstrate adequate safety and efficacy of Adicet’s product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable; and Adicet’s ability to meet production and product release expectations. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in Adicet’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Adicet’s other filings with the U.S. Securities and Exchange Commission, including its quarterly report on Form 10-Q. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law.
ADICET BIO, INC.
Consolidated Statements of Operations and Comprehensive Income
(in thousands, except share and per share amounts)
(Unaudited)
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
$ |
18,450 |
|
|
$ |
28,424 |
|
|
$ |
35,938 |
|
|
$ |
51,238 |
|
General and administrative |
|
|
3,851 |
|
|
|
3,968 |
|
|
|
7,933 |
|
|
|
11,039 |
|
Total operating expenses |
|
|
22,301 |
|
|
|
32,392 |
|
|
|
43,871 |
|
|
|
62,277 |
|
Loss from operations |
|
|
(22,301 |
) |
|
|
(32,392 |
) |
|
|
(43,871 |
) |
|
|
(62,277 |
) |
Interest income |
|
|
1,168 |
|
|
|
1,398 |
|
|
|
2,510 |
|
|
|
3,081 |
|
Interest expense |
|
|
(22 |
) |
|
|
— |
|
|
|
(45 |
) |
|
|
— |
|
Other expense, net |
|
|
(60 |
) |
|
|
(223 |
) |
|
|
(53 |
) |
|
|
(235 |
) |
Loss before income tax provision |
|
|
(21,215 |
) |
|
|
(31,217 |
) |
|
|
(41,459 |
) |
|
|
(59,431 |
) |
Income tax provision |
|
|
(143 |
) |
|
|
— |
|
|
|
(143 |
) |
|
|
— |
|
Net loss |
|
$ |
(21,358 |
) |
|
$ |
(31,217 |
) |
|
$ |
(41,602 |
) |
|
$ |
(59,431 |
) |
Net loss per share, basic and diluted |
|
$ |
(1.99 |
) |
|
$ |
(5.48 |
) |
|
$ |
(3.87 |
) |
|
$ |
(10.40 |
) |
Weighted-average common shares used in computing net loss per share, basic and diluted |
|
|
10,745,553 |
|
|
|
5,692,816 |
|
|
|
10,748,058 |
|
|
|
5,713,182 |
|
Other comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Unrealized loss on treasury securities, net of tax |
|
|
(68 |
) |
|
|
(32 |
) |
|
|
(207 |
) |
|
|
(57 |
) |
Total other comprehensive income |
|
|
(68 |
) |
|
|
(32 |
) |
|
|
(207 |
) |
|
|
(57 |
) |
Comprehensive loss |
|
$ |
(21,426 |
) |
|
$ |
(31,249 |
) |
|
$ |
(41,809 |
) |
|
$ |
(59,488 |
) |
ADICET BIO, INC.
Consolidated Balance Sheets Information
(in thousands)
(Unaudited)
|
|
June 30, |
|
|
December 31, |
|
||
Cash, cash equivalents, and short-term investments in treasury securities |
|
$ |
118,190 |
|
|
$ |
158,530 |
|
Working capital |
|
|
102,762 |
|
|
|
139,395 |
|
Total assets |
|
|
148,166 |
|
|
|
192,355 |
|
Accumulated deficit |
|
|
(656,299) |
|
|
|
(614,697) |
|
Total stockholders’ equity |
|
|
120,138 |
|
|
|
159,210 |
|
Adicet Bio, Inc.
Investor and Media Contacts
Anne Bowdidge
abowdidge@adicetbio.com
Penelope Belnap
Precision AQ
Penelope.belnap@precisionaq.com